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Metformin is the first line drug for type 2 diabetes but its molecular mechanisms
remain unclear. Here, we have studied the acute effect of a therapeutically relevant
intrahepatic concentration of metformin on glucose production from lactate. We
selected the perfused rat liver as experimental system since it enables the complete
control of drug dosage. We used MALDI (matrix-assisted laser desorption/ionization)
mass spectrometry imaging to estimate the concentration of metformin in the livers
and we measured the concentration of glucose in the effluent medium under basal
conditions and following lactate addition. MALDI mass spectra of thin-sections of freeze-
clamped rat liver perfused with metformin showed a peak at 130.16 m/z which was
unambiguously assigned to metformin. The mass spectrometric detection limit was at
a tissue concentration of about 250 nM, and uptake of metformin from the perfusion
medium to the liver occurred with a Km of 0.44 mM. Metformin was evenly distributed
in the liver irrespective of its concentration in the perfusion medium and the duration of
a perfusion. At a parenchymal concentration of 30 µM, metformin did not induce any
significant suppression of the basal or lactate-induced glucose release from the liver.
These results show that matrix-assisted laser desorption/ionization mass spectrometry
imaging can be applied to estimate the tissue concentration and distribution of
metformin in a therapeutically relevant micromolar concentration range. Our findings
challenge the view that metformin causes an inhibition of glucose release from the
liver by an acute inhibition of mitochondrial glycerol 3-phosphate dehydrogenase (EC
1.1.5.3).
Keywords: metformin, diabetes, mass spectrometry imaging, liver, gluconeogenesis, lactate
Abbreviations: HCCA, α-cyano 4-hydrocinnamic acid; MALDI-MSI, matrix-assisted laser desorption/ionization mass
spectrometry imaging; T2D, type 2 diabetes; TOF, time-of-flight.
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INTRODUCTION
Metformin is a hydrophilic biguanide (1,1-dimethylbiguanide)
compound currently prescribed to more than 100 million
persons for the treatment of type 2 diabetes (T2D) (Maruthur
et al., 2016). Metformin is also used in comorbidities of T2D
including polycystic ovary syndrome (Patel and Shah, 2017) and
non-alcoholic fatty liver disease (Rouabhia et al., 2014). T2D
is associated with an increased risk of both Alzheimer’s disease
and vascular dementia (Biessels et al., 2006), and some studies
indicate that metformin may have a direct neuroprotective effect
(Patrone et al., 2014). Patients under treatment with metformin
for T2D have a decreased mortality from cancer as revealed by
several retrospective pharmaco-epidemic studies (Evans et al.,
2005; Currie et al., 2009; Libby et al., 2009; Zhang et al., 2012).
These encouraging discoveries have generated much interest
in the repositioning of metformin for use in diseases other
than T2D.
Metformin is highly water soluble and its uptake into tissues
is mediated by the organic cation transporters OCR1/SLC22A1,
OCR2/SLC22A2, the multidrug and toxin extrusion transporters
MATE1/SLC47A1 and MATE2/SLC47A2, and the plasma
membrane monoamine transporter (Christensen et al., 2011).
Oral metformin administration at a therapeutic dose in humans
results in a maximal plasma concentration of about 10 µM
(Tucker et al., 1981; Christensen et al., 2011). In rodents,
metformin has been shown to accumulate into the gut, liver,
kidney, and skeletal muscle (Wilcock and Bailey, 1994; Quinn
et al., 2013), while less is known about the uptake into
the CNS and its various regions. Metformin can penetrate
into certain tumors, and concentrations reaching 100 µM
have been measured in xenograft-bearing mice following oral
administration (Chandel et al., 2016; Dowling et al., 2016).
Several biochemical effects of metformin have been studied
in detail including (i) an inhibition of complex I of the
mitochondrial respiratory chain (El-Mir et al., 2000; Owen et al.,
2000; Bridges et al., 2014), (ii) an activation of AMP-dependent
protein kinase (Zhou et al., 2001), (iii) a decrease in cAMP with
an attenuated activation of PKA (Miller et al., 2013), and (iv) an
inhibition of mitochondrial glycerol 3-phosphate dehydrogenase
(Madiraju et al., 2014). However, due to the broad range of
concentrations employed in the biochemical studies, frequently
10–100 times higher than that measured in the plasma of patients
(He and Wondisford, 2015), it is challenging to establish causal
links between the biochemical effects of metformin and its
antidiabetic activity, thought to result mainly from a reduction
in the glucose release from the liver (Foretz et al., 2014).
Furthermore, varying effects of metformin on glucose release
have been reported, depending on study design. During ongoing
metformin therapy, a reduction in the glucose release from
the liver can be observed (Jackson et al., 1987; Wu et al.,
1990; Perriello et al., 1994; Hundal et al., 2000), while acute
administration of metformin does not exert any effect on glucose
release (Sum et al., 1992; Widén et al., 1992). In contrast,
perfusion with metformin at a supra-therapeutic concentration
causes an acute reduction in the glucose production from
lactate in rodent liver (Radziuk et al., 1997). It is evident that
several processes influence the onset of the glucose-lowering
effect, including the uptake into the hepatocytes, determined by
plasma membrane transporters, and the response of the cellular
machinery, requiring time for signal transduction events and
transcriptional activation to take place. To clarify the molecular
mechanisms of metformin, it is necessary to control these
processes in the experimental system employed.
This study was performed in order to determine the
acute effect of a therapeutic concentration of metformin on
liver glucose release, employing the perfused rat liver as an
experimental system. We utilized MALDI-MSI (Vaysse et al.,
2017) to determine the uptake and distribution of metformin
into the parenchyma of the liver and we devised conditions for
loading the liver with metformin. We showed that metformin can
be detected at sub-micromolar concentrations in cryo-sections
of freeze-clamped liver using MALDI-MSI, and we determined
the kinetic constants of metformin uptake into the liver. We
assessed the acute effect of metformin on both the basal and the
lactate-induced glucose release, and our findings challenge the
view that the antidiabetic effect of metformin is due to inhibition
of gluconeogensis from lactate through a direct effect on glycerol
3-phosphate dehydrogenase (Madiraju et al., 2014). This study
demonstrates the power of MALDI-MSI for assessing the tissue
concentration and distribution of metformin, and the technique
will be useful for future studies of metformin in T2D, cancer and
neurodegenerative states.
MATERIALS AND METHODS
Animals and Liver Perfusions
This study was carried out in accordance with the
recommendations of the Animal (Scientific Procedures) Act
1986 of the United Kingdom Parliament, Directive 2010/63/EU
of the European Parliament and the Guide for the Care and Use
of Laboratory Animals published by the United States National
Institutes of Health (NHI Publication No. 85-23, revised 1996).
The ethical permit for use of laboratory rats and the protocol
was approved by the Helsinki University Laboratory Animal
Center (permit No. KEK18-016). Male Wistar rats (Envigo,
Netherlands) weighing 140–160 g were starved for 24 h prior
to experiments and anesthetized by intraperitoneal injection
of sodium thiopental (60 mg/kg) (Eriksson et al., 1999). The
abdomen of the rat was opened and heparin (100 IU/kg) was
injected into the inferior vena cava. After 2 min a 24G cannula
was inserted into the portal vein and the liver was perfused with
perfusion medium composed of glucose-free Hank’s balanced
salt medium (HBSS) supplemented with 1.2 mM Ca2+, 0.9 mM
Mg2+, 0.5 mM pyruvate, 0.5 mM glutamine, 0.5 mM acetate,
10 mM Hepes, and 1 µM glucagon when indicated. The medium
was equilibrated with O2/CO2 (19:1) at pH 7.40 ± 0.05, and
the temperature was 37 ± 1◦C (for a scheme of the perfusion
apparatus see Figure 1). The portal vein branches going to the
median, left, and caudate lobes of the liver were occluded by
ligatures, and these lobes were removed, leaving the right lateral
lobe intact. The flow was 5 ml/(min × gram wet liver weight).
An 18G cannula was inserted into the vena cava through the
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FIGURE 1 | Schematic drawing of the perfusion apparatus. Components of the perfusion apparatus: (a) thermostatic bath; (b) bottles containing perfusion medium
equilibrated with O2/CO2 (19:1) at pH 7.40 ± 0.05; (c) manifold; (d) peristaltic pump; (e) thermostat at 37 ± 1◦C; (f) cannula for ingoing medium; (g) cannula inserted
in lower vena cava collecting outgoing medium; (h) and fraction collector.
right atrium of the heart, in order to collect the eﬄuent medium
from the liver in 1 min fractions for glucose determination. The
preparation took less than 10 min from opening the abdomen
of the rat. Following a stabilization period of 5 min, perfusions
were performed according to the experimental protocols detailed
below. After the perfusion experiment, the liver right lateral lobe
was excised and freeze-clamped with liquid nitrogen.
Perfusion Protocols
Four different perfusion protocols were performed as shown
schematically in Figure 2. The assignment of rats to different
groups was randomized. Protocol A served to determine the
concentration of metformin in the perfusion medium required
to reach a parenchymal concentration of 30 µM in 5 min.
Protocols B to D were used to determine the effect of metformin
or ethanol on the basal and lactate-induced glucose release.
Time t = 0 indicates the end of the stabilization period as
described above. In protocol A, livers were perfused with
perfusion medium without metformin for 20 min, followed by
5 min with perfusion medium supplemented with 100, 250,
500 µM, 1 or 2.5 mM metformin, followed by a brief washout
for 20 s with perfusion medium without metformin. The liver
lobe was then resected, immediately freeze-clamped in liquid
nitrogen at −196◦C, and used for analysis by MALDI-MSI. In
protocol B, which was the control, livers were perfused for 10 min
with perfusion medium, followed by 10 min with perfusion
medium supplemented with 5 mM D-lactate. This was followed
by 10 min with perfusion medium and 10 min with perfusion
medium supplemented with 5 mM D-lactate, after which the
liver was freeze clamped. In protocol C, livers were perfused
for 10 min with perfusion medium. At 10 min, the perfusion
medium was supplemented with 5 mM D-lactate. At 20 min,
the D-lactate was omitted and the livers were perfused for 5 min
with perfusion medium supplemented with 400 µM metformin.
At 25 min, livers were perfused for another 5 min with
perfusion medium supplemented with 40 µM metformin until
the end of the perfusion. At 30 min, the perfusion medium was
supplemented with 5 mM D-lactate, and at 40 min the D-lactate
was omitted. In protocol D, livers were perfused for 10 min with
perfusion medium followed by 10 min with perfusion medium
supplemented with 5 mM D-lactate. At 20 min, livers were
perfused for 10 min with perfusion medium supplemented with
25 mM ethanol, followed at 30 min by 10 min with perfusion
medium supplemented with 5 mM D-lactate and 25 mM ethanol.
By performing the transition from basal to lactate-induced
glucose production twice in each perfusion, every liver served as
its own control. This procedure reduced errors due to differences
in the liver lobe size, and variations in the liver metabolism
between the different animals.
Cryo-sections
The freeze-clamped right lateral lobe was cut into 12 µm
thick transversal sections using a Leica CM3050 cryostat
(Leica Microsystems GmbH, Germany), and thaw-mounted onto
indium tin oxide (ITO)-coated MALDI target slides (Bruker
Daltonics, BD, Germany), covered with a nano-structured layer
of TiO2 (Tethis S.p.A., Milan, Italy), which improves tissue
adhesion during the MSI process. Prior to matrix deposition
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FIGURE 2 | Perfusion protocols. Perfusions according to protocol (A) were performed to measure the intrahepatic concentration of metformin and to optimize the
concentration of metformin in the perfusion medium during the loading period. Perfusions according to protocol (B) were control experiments with two periods of
D-lactate (5 mM) challenge (Lactate). Perfusions according to protocol (C) performed to determine the effect of metformin (MF ) on glucose release and its response
to D-lactate. Loading concentration (400 µM) with metformin is indicated in red, and steady state concentration of metformin (40 µM) is indicated by red stripes.
Perfusions according to protocol (D) were performed with 25 mM ethanol (EtOH). For statistical analysis, paired comparisons were made for the efflux glucose
concentration at t = 1 and 21 min, t = 2 and 22 min, and similarly until t = 20 and 40 min, resulting in 10 pairs for basal conditions (Basal) and 10 pairs for
lactate-induced conditions (Lactate), as indicated in the bottom panel.
target slides were dried for 10 min in a SpeedVac SVC200H
(Savant, Farmingdale, NY, United States), and optical images
of the tissues were acquired using a flat-bed scanner (Epson
Perfection V750 Pro) at a resolution of 2400 px/inch.
Deposition of Matrix Substances for
MALDI Mass Spectrometry
A solution of 7 mg/ml of HCCA in 50% acetonitrile/0.1%
trifluoroacetic acid was deposited onto the liver thin-section
using an iMatrixSpray instrument (Tardo Gmbh, Subingen,
Switzerland), applying 10 cycles of deposition, resulting in a
homogeneous coating (0.57± 0.05 µg/cm2) of dry HCCA.
MALDI Mass Spectrometry
Liver thin-sections were scanned with a 150 µm raster on
a Bruker© UltrafleXtreme 2 kHz MALDI-TOF/TOF Mass
Spectrometer in Reflectron positive mode, acquiring in the
20–500 Da mass range and summing 2000 laser shots per
raster position. For analyses of the fragmentation of the parent
ion measurements were made in LIFT MS/MS mode. The
resulting FlexImaging 4.1 (Bruker Daltonics, Bremen, Germany)
files, containing the acquired spectra from the measurement
regions, were imported into SCiLS Lab 2017a software (1Bremen,
1http://scils.de/
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Germany) for subsequent Total ion current (TIC) normalization,
peak alignment, and data visualization.
Quantification of the Mass
Spectrometric Signal of Metformin
To estimate the concentration of metformin in perfused livers
two methods were used to generate a standard curve. In
the standard under the tissue method, known quantities of
metformin were dissolved in water and spotted directly onto
the ITO slides. The applied metformin solution was allowed to
dry, and the metformin-containing spots were marked. Liver
thin-sections from control livers which had been perfused
without metformin where then placed over of the metformin
spots. In the standard over the tissue method, known quantities
of metformin dissolved in water were applied on top of mounted
liver thin-section. The applied metformin solution was allowed
to dry and the areas occupied by the dried metformin-containing
spots were marked before matrix deposition. Standard curves
were generated by the standard under, and standard on top
of the thin-section methods, using the median intensity of
the metformin signal in each spot region. For calculating the
parenchymal metformin concentration, the mean values of the
standard under and standard on top of the thin-section methods
were used. Signal-to-noise ratio was calculated using FlexAnalysis
version 3.4.
Glucose Determination
The glucose concentration of the eﬄuent medium was measured
as NADP reduction at λ = 340 nm using a coupled enzyme
assay. The reaction mixture contained 1 mM ATP, 2.5 mM NADP,
hexokinase (0.1 U), and glucose 6-phosphate dehydrogenase
(0.1 U) dissolved in HBBS medium supplemented with 1.2 mM
Ca2+, and 0.9 mM Mg2+. The reaction was allowed to proceed
for 30 min at room temperature after the addition of the enzyme
mixture. Absorbance was measured using an EnSpire Multimode
plate reader (Perkin Elmer). The average concentration of glucose
in the eﬄuent medium during the first 10 min of the perfusion
was normalized to one, because the size of the right lateral lobe
varied between different animals. The glucose release during the
first 10 min of the perfusion was 64.9 ± 18 µM (mean ± SD,
n = 30 for all experimental groups together). The person
performing the glucose analyses had no knowledge about the
experimental group of the samples.
Statistical Analysis
The data and statistical analysis comply with the
recommendations on experimental design and analysis in
pharmacology (Curtis et al., 2015). For the MALDI-MSI data
spectra were normalized with the TIC method (Deininger et al.,
2011) which normalizes every spectrum separately by dividing
each spectrum intensity by the sum of all its intensities. Peaks
were aligned to local maxima (Alexandrov and Kobarg, 2011) by
setting the minimal interval width to 0.125 m/z. Baseline removal
was not performed.
Data from glucose determinations were collected in Excel
(Microsoft) and statistical analysis was performed using the IBM
SPSS Statistics 24.0 software (IBM Corporation, Armonk, NY,
United States). The raw data were analyzed independently by two
of the co-authors to ensure correctness of the conclusions. To test
for statistically significant differences in glucose release, pairwise
comparisons were made of the eﬄuent glucose concentration at
t = 1 min with t = 21, t = 2 min with t = 22 min, and similarly
until t = 20 min which was compared with t = 40 min, for
each individual rat liver. For each perfusion, 20 measurement
pairs were hence formed, of which the 10 pairs where for
basal glucose release and 10 pairs for lactate-induced glucose
release, as indicated in Figure 2, lower panel. Testing for normal
distribution was performed using the Shapiro–Wilk test, and
for statistical significance using Student’s t-test under the null
hypothesis that there was no difference in glucose concentration
before and after addition of metformin or ethanol, respectively.
A p < 0.01 was considered significant and this was marked with
an asterisk in the graph.
Chemicals and Reagents
Metformin was from Sigma-Aldrich (pharmaceutical secondary
standard grade, Lot#LRAA8975). HCCA was of mass
spectrometry grade form Sigma-Aldrich. All other chemicals
were of highest grade and purchased from Sigma-Aldrich.
RESULTS
Mass Spectrometric Properties of
Metformin
In order to select the best condition for the ionization
of metformin we tested several different MALDI matrix
substances on the metformin-containing liver thin-sections,
including HCCA, 2-picolinic acid, ferulic acid, sinapic acid, and
2,5-dihydroxy benzoic acid. This revealed that HCCA yielded
the best results in terms of peak shape and intensity (data
not shown). We first characterized the MALDI TOF mass
spectra of thin-sections from rat livers that had been perfused
with 500 µM metformin according to protocol A (Figure 3A).
A distinct peak at 130.16 m/z corresponding to the molecular
weight of metformin was observed specifically in thin-sections
of metformin-treated liver. To validate the assignment of the
130.16 m/z peak we performed MS/MS analyses using LIFT
fragmentation (Figure 3A, inset), which yielded a peak pattern
consistent with the theoretical and measured fragmentation
of metformin (MassBank data base, entry KO003376), and
literature data (Michel et al., 2015). Five ions could be detected,
corresponding to the fragment ions of metformin (Figure 3B).
The control liver thin-sections did not yield any fragmentation
spectrum due to the absence of detectable precursor ions at
130.16 m/z (Figure 3C). These findings confirmed that the
130.16 m/z peak was metformin.
Estimation of the Parenchymal
Metformin Concentration
In order to estimate the concentration of metformin in the
perfused liver we used two different methods, standard under
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FIGURE 3 | Mass spectrometric properties of metformin in liver tissue background. Thin-sections of freeze-clamped rat livers perfused with or without metformin
were analyzed by MALDI TOF mass spectrometry. (A, main image) Shows the mass spectrum of liver tissue containing metformin, the peak at 130.16 m/z
corresponding to the parent molecular mass of metformin is indicated with an arrowhead. (A, inset) Shows the LIFT MS/MS spectrum of the 130.16 m/z parent ion
with the peaks of fragment ions of metformin. (B) Structure of metformin and detected fragment ions indicated with letters. (C) Shows the mass spectrum of liver
tissue perfused without metformin, lacking the peak at 130.16 m/z (cross). Arbitrary intensity (A.I.) represents the unit reported by the FlexImagingTM software
package.
and standard on top of the thin-section as described in Section
“Materials and Methods.” The results of these experiments are
shown in Figure 4A, where known quantities of metformin were
spotted either under or above thin-sections of rat liver perfused
according to protocol A without metformin. The intensity of
the peak at 130.16 m/z is shown in pseudo-coloration, and the
borders of the regions of interest (ROI) of the thin-sections
containing metformin are marked in red. The intensity of the
peak at 130.16 m/z was plotted for each pixel in the ROIs and
the resulting histograms with the distribution in pixel values are
shown in Figure 4B. The standard curve was constructed by
calculating the average of the respective median value obtained
for the standard under and standard on top of the thin-section
methods (Figure 4C), in order to simulate the condition of
metformin being embedded within the tissue matrix. To estimate
the mass spectrometric detection limit of metformin in the
liver, we incrementally decreased the metformin concentration,
and the results yielded that, at a concentration of 250 nM,
the metformin peak at 130.16 m/z could be detected at a
signal-to-noise ratio of three (Figure 4D).
Uptake of Metformin by the Perfused
Liver
We first established the concentration of metformin required in
the perfusion medium to reach a concentration of 30 µM in
the liver parenchyma, using perfusion protocol A. The perfusion
medium was supplemented with metformin at concentrations
ranging from 100 µM to 5 mM for 5 min, followed by a brief
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FIGURE 4 | Estimation of the metformin concentration in the liver parenchyma. (A) Known quantities of metformin were spotted either on top of (Over) or under
(Under) thin-sections of rat livers perfused without metformin: (a) 5 µM, (b) 10 µM, (c) 25 µM, and (d) 50 µM. (B) Box plot of the pixel values obtained for each spot
of metformin. Box lines are median, first and third quartiles, and whiskers show the 2nd and 98th percentiles. The average number of pixels for each ROI was 896.
(B, inset) Shows the peak intensity for 5 and 10 µM metformin. (C) Standard curve with linear regression calculated from the average of the values obtained by
applying standard on top of and under the thin-section, respectively. (D) The mass spectrum of a liver thin-section with 250 nM metformin, as indicated (arrowhead).
Arbitrary intensity (A.I.) is reported as in Figure 3.
washout with perfusion medium lacking metformin. Liver lobes
were freeze-clamped and analyzed by MALDI-MSI, and the
parenchymal metformin concentration was assessed using the
established standard curve (Figure 5A). For the perfused livers,
we used the median values of the peak at 130.16 m/z for all
pixels from the whole area of the liver thin-section. As shown
(Figure 5A), metformin was evenly distributed in the liver lobe
with local variations in the range of less than 20%. We then
analyzed the intrahepatic metformin concentration as a function
of the metformin concentration used in the perfusion medium
according to protocol A. These results indicated that metformin
was effectively accumulated into the liver parenchyma with an
estimated Km of 0.44 mM and a Vmax of 0.2 µmol/(gxmin)
(Figures 5C,D). Based on these results, we selected to use 400 µM
metformin for the loading period, and 40 µM for the steady
state in the perfusions according to protocol C. To ascertain that
the concentration of metformin remained constant until the end
of the experiment (protocol C), we freeze-clamped livers at the
end of the perfusion and determined their metformin content.
The results of these experiments (Figure 5B), revealed that the
concentration of metformin remained stable at about 30 µM
during the course of the experiment. As anticipated, there was
no detectable signal above baseline at 130.16 m/z in control livers
in the absence of metformin, or in livers perfused with ethanol
(Figure 5B).
Effect of Metformin on Glucose Release
Rats were starved 24 h prior to experiments, to deplete the
liver from glycogen. Livers were perfused according to protocol
B using 5 mM D-lactate to promote glucose release. Figure 6
shows the concentration of glucose in the eﬄux medium during
the course of the perfusion. It can be appreciated that addition
of lactate induced a marked increase in the glucose release
of about 1.5-fold over the basal level, and this increase was
quantitatively similar during the first and second period with
lactate (Figure 6, Control). In the next series of perfusions
(protocol C), we supplemented the perfusion medium with
metformin starting at t = 20 min in order to study the effect of
metformin on the glucose release. The result of this experiment
revealed that metformin did not induce any significant
suppression neither in the basal glucose release nor in the lactate-
induced increase in glucose release (Figure 6, Metformin). In the
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FIGURE 5 | Uptake of metformin into the perfused liver. (A) Rat livers were perfused according to protocol A with metformin in the perfusion medium, (a) 250 µM, (b)
500 µM, and (c) 1 mM. (B) Rat livers were perfused according to protocol C (Metformin), protocol D (EtOH), or protocol B (Control), and freeze-clamped the end of
the perfusion. The metformin concentration was 30 ± 10 µM (n = 5). (C) Rat livers were perfused according to protocol A. Box plot of the signal intensity of
metformin versus the concentration of metformin used in the perfusion medium. Box plot parameters were as in Figure 4. (D) Plot of the signal intensity versus
metformin concentration. A double reciprocal plot (not shown) yielded a Km of 0.44 mM. Arbitrary intensity (A.I.) is reported as in Figure 3.
positive controls (protocol D), we supplemented the perfusion
medium with 25 mM ethanol starting at t = 20 min. The result
of this experiment revealed that ethanol induced a significant
suppression of both the basal glucose release and the lactate-
induced glucose release (Figure 6, EtOH).
DISCUSSION
In this study, we have devised conditions for delivery of a
therapeutic concentration of metformin to the perfused rat liver,
and we have investigated the acute effects of metformin on
glucose release. To estimate the concentration and distribution
of metformin we have used MALDI-MSI, which revealed that
the drug can be detected at sub-micromolar concentration in the
liver. We have discovered that metformin is accumulated from
the perfusion medium into the liver with kinetic values indicating
OCT1-mediated uptake (Wang et al., 2002). We found that
metformin did not suppress the basal rate of glucose production,
or glucose production forced by high lactate. This finding
challenges the view that metformin causes an acute inhibition
of glycerol 3-phosphate dehydrogenase (Madiraju et al., 2014),
inducing a shift in the NADH/NAD ratio, thereby attenuating
gluconeogenesis.
The complex chemical composition of the liver and its large
number of endogenous low molecular weight metabolites renders
the identification of peaks in the mass spectrum challenging.
To unambiguously assign the peak of metformin in the mass
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FIGURE 6 | Glucose release from the perfused liver. Rat livers were perfused according to protocol B (Control), C (Metformin), or D (EtOH). The presence of lactate in
the medium is indicated with bars (Lactate). The effluent medium was collected in 1 min fractions following passage through the liver. The glucose concentration of
the effluent medium was determined using a coupled enzyme assay (mean values ± SD, n = 10 for each experimental group). Concentrations were normalized by
setting the average of the 10 first measurement points to one. For each rat, the glucose concentration of the effluent medium after addition of metformin or ethanol
was compared to that before addition. Statistical significance (p < 0.01) was assessed as described in Section “Statistical Analysis.”
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FIGURE 7 | Redox shuttles during gluconeogenesis. During gluconeogenesis from lactate, e.g., during exercise, pyridine nucleotides undergo continuous redox
cycling to support the redox reactions of the involved pathways. Imbalances in the redox balance of the pyridine nucleotide couples (marked in green), are adjusted
by redox shuttle pathways including the glycerol 3-phosphate shunt, feeding excess electrons into the mitochondrial respiratory chain leading to reduction of oxygen.
Ethanol oxidation to acetic acid by alcohol dehydrogenase and aldehyde dehydrogenase leads to a build-up of NADH and thereby an inhibition of glucose release as
indicated in the scheme. Metformin has been proposed to exert its antidiabetic effect by inhibiting mitochondrial glycerol 3-phosphate dehydrogenase (EC 1.1.5.3)
(Madiraju et al., 2014), as indicated in the scheme.
spectrum of the liver tissue we used both the MS and MS/MS
modalities. The resulting MS/MS mass spectrum showed a
fragmentation pattern consistent with that derived for metformin
based on its structure, in agreement with published observations
(Michel et al., 2015). The 130.16 m/z peak was assigned to
metformin, and there was no significant background from
endogenous compounds in that region. This allowed for an
estimation of the detection limit to <250 nM for metformin in
the liver. This is well below the measured therapeutic metformin
concentration in human plasma (Tucker et al., 1981; Christensen
et al., 2011), as well as that in rodent tissues (Wilcock and
Bailey, 1994), and in mouse xenograft tumors (Chandel et al.,
2016; Dowling et al., 2016). This indicates that MALDI-MSI
can be employed to determine the distribution of metformin in
organ systems in general. Our results indicated that metformin
was effectively accumulated into the liver parenchyma during
the 5-min loading period. In the liver, uptake of metformin
is mediated primarily by the OCT1 transporter with a Km of
0.377 µM (Wang et al., 2002), which is in agreement with the
uptake velocity derived from our MALDI-MSI measurements.
Quantification by mass spectrometry poses several challenges,
and unique standard curves need be determined for each
experimental setting, depending of the chemical background
of the sample, the matrix deposition method, the ionization
method, and the detector system. Orally or intravenously
administered drugs reach the target tissue through the vascular
system and become embedded within tissue matrix. This renders
the quantification by external standards problematic due to
the differences in ionization efficiency between embedded and
external drug molecules. To solve these problems, we applied
known quantities of a standard solution of metformin both
under and on top of liver thin-sections. The results of the
MALDI-MSI measurements indicated that applying the standard
under the tissue thin-section gave a somewhat higher signal
intensity than for standard applied on top of the thin-sections,
probably because the former was located closer to the conducting
surface of the glass slide, hence facilitating the ionization. To
mimic the situation where the drug is embedded within the
tissue matrix we used the average values obtained from the
standard under and standard on top measurements. Alternative
quantification methods employing tissue homogenates have been
described (Jadoul et al., 2015), which are promising, but will
require further scrutiny to ascertain the chemical integrity of the
tissue.
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To investigate the acute metabolic effects of metformin we
devised an experimental protocol to measure glucose release both
at its basal level and when forced by high lactate. By performing
the transition from basal to lactate-induced glucose release two
times during each perfusion, without and with metformin, each
liver served as its own control. This protocol reduced variations
in glucose release arising from differences in the size of the liver
lobe and from individual differences in the liver metabolism
between the animals. During gluconeogenesis from lactate several
reaction pathways are operating to maintain the equilibrium in
the redox state of the NADP/NAD and NADPH/NADP couples,
as shown in Figure 7. Most importantly the glycerol 3-phosphate
shuttle, resulting in the oxidation of NADH and the transfer of
its electrons to the mitochondrial respiratory chain, is required
for the continuous conversion of lactate to glucose. It has been
proposed that the antidiabetic effect of metformin is due to an
inhibition of the enzyme glycerol 3-phosphate dehydrogenase
leading to an accumulation of NADH, and hence to a diminished
conversion of lactate to glucose (Madiraju et al., 2014). Our
results do not lend support to this mechanism since we did
not observe any significant suppression neither of the basal
glucose release nor of the lactate-induced glucose release. In
contrast, supplementing the medium with ethanol instead of
metformin had an immediate inhibitory effect on the glucose
release, consistent with an accumulation of reduced pyridine
nucleotides caused by the oxidation of ethanol into acetic acid.
Our findings are in line with human studies showing that
metformin does not exert any acute suppressive effect on
glucose release from the liver when administered intravenously
(Sum et al., 1992) or orally (Widén et al., 1992). Collectively,
these human studies and our organ perfusion data suggest
that metformin, at a therapeutically relevant low 10−5 M
concentration, does not affect glucose release through direct
inhibition of some target enzyme(s). Instead, the time lag
required for metformin to take effect, points to the necessity of
signal transduction events and transcriptional activation to occur,
in consequence, leading to a gradual remodeling of the metabolic
web, requiring days to reach maximal effect (Bailey, 1992).
Therefore, it is likely that the anti-diabetic effect of metformin to
a major extent is mediated through molecular mechanisms that
require transcriptional regulation, leading to a reprogramming
of the metabolic network. This is supported by the finding
that common gene variants, which to the largest extent affect
the response to metformin, are metformin transporters and
transcription factors, such as HNR1A, HNF4A, PPARgC1A,
MEF2A, MEF2D (Jablonski et al., 2010), and not enzymes of the
metabolic pathways.
Our study shows that the metformin concentration can
estimated by MALDI-MSI in rat liver, with a maximum
sensitivity below the therapeutic concentration range. Therefore,
MALDI-MSI will likely become a valuable tool to investigate the
penetration and distribution of metformin into other solid tissues
in rodents and humans. The MALDI-MSI technique may assist in
providing essential data in future studies of metformin in tumor
and neurodegenerative therapies.
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